Should we recommend neuroaminidase inhibitors for influenza?

Clinical Microbiology and Infection

Volumn 20, Issue 12, 2014, Pages O979-O980

  Leibovici, L ^a,b   Paul, M ^c  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

ANTAGONISTS AND INHIBITORS; HUMAN; INFLUENZA, HUMAN; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; TREATMENT OUTCOME;

EID: 84920282042     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12708     Document Type: Article

References (4)

1. Jefferson T, Jones MA, Doshi P et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014; 4: CD008965.
2. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2: 395-404.
3. Hiba V, Chowers M, Levi-Vinograd I et al. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. J Antimicrob Chemother 2011; 66: 1150-1155.
4. Nougairede A, Charrel RN, Raoult D. Models cannot predict future outbreaks: A/H1N1 virus, the paradigm. Eur J Epidemiol 2011; 26: 183-186.